Members of the ErbB family of transmembrane tyrosine kinase growth factor receptors, which includes EGFR and HER-2, are frequently overexpressed or constitutively activated in pancreatic adenocarcinoma and their expression has been shown to correlate with worse outcome and multiple drug resistance (32,33). This evidence concerns the gene EGFR and pancreatic adenocarcinoma.